Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 27, Issue 7, Pages 1145-1148Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458520914818
Keywords
Autologous haematopoietic stem cell transplantation; alemtuzumab; aggressive multiple sclerosis; treatment
Categories
Ask authors/readers for more resources
Autologous haematopoietic stem cell transplantation (aHSCT) could be considered as a rescue treatment for multiple sclerosis patients with persistent disease activity during alemtuzumab treatment, as short-term safety and efficacy data showed good outcomes.
The management of multiple sclerosis patients with persistent disease activity under alemtuzumab treatment is not established yet. Concerns have been raised on the safety of autologous haematopoietic stem cell transplantation (aHSCT) after alemtuzumab treatment because of the risk of serious infectious adverse events. We report short-term safety and efficacy data from three patients treated with aHSCT following alemtuzumab treatment. Early adverse events were consistent with expected transplant toxicities. All patients were free of disease activity at the last follow-up. Our data suggest that aHSCT can be considered as a rescue treatment strategy for MS patients with persistent disease activity during alemtuzumab treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available